Advertisement

Topics

Biosimilars set to take on Oncology after a new Market Authorization

06:28 EST 23 Feb 2017 | Labiotech.eu

The European Commission has approved Truxima, the world’s first biosimilar monoclonal antibody (mAb)  with an oncology indication. Based in South-korea, Celltrion Healthcare is setting foot in the European oncology market with the approval of Truxima, a biosimilar to Roche’s Mabthera (rituximab). The ...

This awesome article Biosimilars set to take on Oncology after a new Market Authorization appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Biosimilars set to take on Oncology after a new Market Authorization

NEXT ARTICLE

More From BioPortfolio on "Biosimilars set to take on Oncology after a new Market Authorization"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...